We enrolled 25 cases with severe preeclampsia, 25 controls with chronic hypertension, and 25 healthy controls without hypertension from a cohort of women receiving care at Brigham and Women's Hospital from March 2012 through March 2013. Institutional review board approval was obtained through the Partners Human Research Committee, and subjects gave informed consent. All procedures followed were in accordance with institutional guidelines. Methods Abstract-Kidney injury with proteinuria is a characteristic feature of preeclampsia, yet the nature of injury in specific regions of the nephron is incompletely understood. Our study aimed to use existing urinary biomarkers to describe the pattern of kidney injury and proteinuria in pregnancies affected by severe preeclampsia. We performed a case-control study of pregnant women from Brigham and Women's Hospital from 2012 to 2013. We matched cases of severe preeclampsia (n=25) 1:1 by parity and gestational age to 2 control groups with and without chronic hypertension. Urinary levels of kidney injury molecule-1 and complement components (C3a, C5a, and C5b-9) were measured by enzyme-linked immunosorbent assay, and other markers (albumin, β2 microglobulin, cystatin C, epithelial growth factor, neutrophil gelatinase-associated lipocalin, osteopontin, and uromodulin) were measured simultaneously with a multiplex electrochemiluminescence assay. Median values between groups were compared with the Wilcoxon signed-rank test and correlations with Spearman correlation coefficient. Analysis of urinary markers revealed higher excretion of albumin and kidney injury molecule-1 and lower excretion of neutrophil gelatinase-associated lipocalin and epithelial growth factor in severe preeclampsia compared with chronic hypertension and healthy controls. Among subjects with severe preeclampsia, urinary excretion of complement activation products correlated most closely with kidney injury molecule-1, a specific marker of proximal tubule injury (C5a: r=0.60; P=0.001; and C5b-9: r=0.75; P<0.0001). Taken together, we describe a pattern of kidney injury in severe preeclampsia that is characterized by glomerular impairment and complement-mediated inflammation and injury, possibly localized to the proximal tubule in 
K
idney injury with proteinuria is a characteristic feature of preeclampsia, yet the nature of injury in specific regions of the nephron is incompletely understood. Glomerular barrier dysfunction, characterized by glomerular endotheliosis 1,2 and podocyte loss, 3, 4 has been emphasized in severe preeclampsia because marked albuminuria is a hallmark feature of disease. 5, 6 However, inflammation and injury to the proximal tubule also contributes to disease pathogenesis in many kidney disorders. [7] [8] [9] [10] Considering that the tubulointerstitium accounts for >90% of kidney volume and that tubulointerstitial disease may occur independent of glomerular disease, 11 it is critical that urinary protein assessment in preeclampsia consider both glomerular and nonglomerular patterns of injury.
Although the cause of preeclampsia is incompletely understood, 12, 13 active disease is most often characterized as a multiorgan, systemic inflammatory disorder with endothelial cell activation, intravascular volume depletion, hypertension, and kidney injury. [14] [15] [16] Complement activation is central to the systemic inflammatory response in preeclampsia, possibly in response to apoptotic or necrotic trophoblast debris at the placental interface and in systemic circulation. 15, [17] [18] [19] Marked urinary excretion of complement components in severe preeclampsia 20 suggests that complement-mediated kidney injury is a key feature of disease. To map out potential sites of complement-mediated kidney injury in preeclampsia, we sought to measure a panel of urinary biomarkers linked to specific regions of the nephron [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] (Figure 1 ), among pregnant women with and without preeclampsia.
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have been described previously, 20 but key aspects are summarized below with modifications pertinent to this investigation. Pregnancies with multiple gestation or major fetal anomalies were excluded. Preeclampsia cases were recruited from the labor and delivery ward or antepartum units and defined as severe by standard criteria as previously detailed. 16, 20 Controls with pre-existing chronic hypertension and healthy controls without hypertension or renal disease were recruited from prenatal clinics and matched 1:1 to severe preeclampsia cases by parity (nulliparous or multiparous) and gestational age (±2 weeks).
Urine samples were collected on the day of enrollment via a random clean-catch specimen or Foley catheter. Samples were centrifuged at −4°C, with supernatant aliquoted and stored at −80°C. Complement activation was determined by human enzyme-linked immunosorbent assay to measure C3a/C3a desArg (C3a), C5a/C5a desArg (C5a), and C5b-9 concentrations (BD Biosciences, San Jose, CA). Urinary kidney injury molecule-1 (KIM-1) levels were determined by human quantikine enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). Urine samples were analyzed after 1:2 dilution (C3a, C5a, C5b-9) or no dilution (KIM-1) followed by 1:20 to 1:200 dilution if protein levels exceeded the top standard. Intra-assay coefficient of variation was 5.6% (C3a), 3.4% (C5a), 4.5% (C5b-9), and 3.4% (KIM-1); interassay coefficient of variation assessed based on quality control pool tested on each enzyme-linked immunosorbent assay plate was 11.1% (C3a), 13.8% (C5a), 7.4% (C5b-9), and 12.6% (KIM-1). Assay values <2 SDs of the blank were considered below the lower limit of detection, which were 0.013 (C3a), 0.012 (C5a and C5b-9), and 0.005 ng/mL (KIM-1). Urine creatinine was determined with the Parameter Creatinine Assay Kit (R&D Systems). Clinical variables and laboratory parameters were abstracted from medical records, and the syndrome of hemolysis, elevated liver enzymes, and low platelets was diagnosed by established criteria. 37 All other kidney markers (albumin, β2 microglobulin [B2M], cystatin C, epithelial growth factor [EGF], neutrophil gelatinase-associated lipocalin [NGAL], osteopontin, uromodulin) were measured simultaneously with a multiplex electrochemiluminescence assay, human Kidney Injury Panel 5 (Meso Scale Discovery, Rockville, MD). Urine samples were analyzed in duplicate after 1:100 dilution followed by 1:1000 to 1:10 000 dilution if protein levels exceeded the top standard. Two quality control pools were tested at different dilutions matching the linearity range on each assay plate to assess interassay variation. Intra-assay coefficient of variation was 3.5% (albumin), 6.0% (B2M), 7.6% (cystatin C), 0.79% (EGF), 3.3% (NGAL), 7.3% (osteopontin), and 0.92% (uromodulin); interassay coefficient of variation was 3.2% (albumin), 9.4% (B2M), 7.7% (cystatin C), 4.6% (EGF), 7.5% (NGAL), 2.9% (osteopontin), and 5.7% (uromodulin). The lower limit of detection was a calculated concentration based on a signal 2.5 SDs above the background (zero calibrator blank) and were 226 (albumin), 1.82 (B2M), 9.81 (cystatin C), 0.057 (EGF), 2.66 (NGAL), 69.9 (osteopontin), and 52.5 pg/mL (uromodulin).
Statistics
Urine protein concentrations are presented as medians (interquartile range) because of skewed distribution and presence of zero values. Significant differences between groups were determined with the Wilcoxon signed-rank test for nonparametric testing of matched groups. Correlations between biomarkers were determined using Spearman correlation coefficient for nonparametric tests or Pearson correlation coefficient for log-transformed data. The study was powered to detect a 2-fold difference in urinary protein concentrations, assuming SD of 100%, α=0.05, and β=0.80. For correlations between our panel of 8 kidney biomarkers and individualcomplement components (C3a, C5a, and C5b-9), Bonferroni correction was applied with significance determined by α=0.01. Data analysis was performed with Stata 10.0 (StataCorp, College Station, TX).
Results
The baseline characteristics of the 3 study groups have been published previously 20 and are presented in the Table. Controls were matched to severe preeclampsia cases by parity and gestational age at enrollment.
Absolute urinary protein levels of all measured kidney markers in cases and controls are displayed in Figure 2 , with concentrations varied for display purposes. Levels of urine albumin, a marker of glomerular barrier dysfunction, 2, 21, 22 were markedly elevated in subjects with severe preeclampsia compared with both control groups. Albumin levels were no different between controls with chronic hypertension and healthy controls without hypertension. These findings were unchanged after adjustment for urine creatinine (Table S1 in the online-only Data Supplement).
Urinary levels of KIM-1, a specific marker of proximal tubule injury, 30 were also significantly greater in severe preeclampsia compared with both control groups. Concentrations of NGAL and EGF, proposed markers of acute kidney injury and tubular damage, 28, 29, 31, 32 were significantly lower in severe preeclampsia compared with controls. Levels of cystatin C, a sensitive marker of glomerular filtration because of its small size, 26, 27 were increased in chronic hypertension but not severe preeclampsia. Other measured urinary markers of kidney injury (B2M, osteopontin, and uromodulin) were not different between any of the study groups. These findings remained unchanged after adjustment for urine creatinine (Table S1 ).
In this same cohort of subjects, we recently reported that urinary excretion of complement components was increased in severe preeclampsia. 20 Thus, we investigated correlations between these previously measured complement markers (C3a, C5a, and C5b-9) and the kidney markers measured in 31, 32 osteopontin (OPN), [33] [34] [35] and uromodulin (UMOD). 33, 36 by guest on August 25, 2017 http://hyper.ahajournals.org/ Downloaded from this analysis. To explore associations in active disease, we focused our analysis on subjects with severe preeclampsia (n=25), and the correlation results are provided in Table S2 . Of the kidney markers assessed, only KIM-1 levels correlated significantly with urinary complement levels. KIM-1 did not correlate with C3a, but correlated well with increased C5a and C5b-9 ( Figure 3 ). Other measured kidney markers were not statistically significant after application of Bonferroni correction for multiple comparisons (α=0.01). Urinary levels of albumin were markedly increased in preeclampsia, but correlation with complement markers was modest. Albumin levels also failed to correlate significantly with KIM-1 (r=0.35; P=0.09).
Discussion
Kidney injury in preeclampsia is most commonly defined by the total excretion of urinary protein in 24 hours or by the ratio of total urine protein to creatinine in a random urine collection. 16, 38 However, the validity of standard urinary protein measurements for the diagnosis of preeclampsia has been questioned, 38, 39 partly because the extent of proteinuria in preeclampsia does not correlate well with disease severity. Although the importance of absolute urine protein levels in severe preeclampsia is questioned, our study confirms that there is significant glomerular barrier impairment as indicated by marked albuminuria in active disease. Urinary albumin levels were ≈75× greater in severe preeclampsia compared with healthy controls and 40× greater than controls with chronic hypertension. In preeclampsia, the integrity of the glomerular basement membrane may be impaired by increased serum levels of soluble fms-like tyrosine kinase-1, which sequesters vascular endothelial growth factor. 40, 41 Urinary excretion of podocytes from the glomerulus 42 and loss of negative charge density at the glomerular membrane also contribute to filtration of albumin in the urine. 43, 44 Filtered albumin, or compounds carried by albumin, may trigger inflammation with direct injury to proximal tubule cells. 45 Albumin may also compete for reabsorption at the proximal tubule with low-molecular-weight proteins such as B2M, cystatin C, and NGAL. 46 Alternatively, filtered proteins may be excreted in the urine because of impaired proximal tubule reabsorption of other cause. 45 Although the proximal tubule serves a critical role in disease states defined by proteinuria, the cause of proximal tubule injury in preeclampsia is unclear. In our investigation, urinary excretion of B2M and cystatin C was no different, or lower, in subjects with severe preeclampsia. This finding argues against diffuse impairment of proximal tubule reabsorption, which would lead to increased excretion of filtered proteins. Interestingly, we did find that urinary excretion of KIM-1, a specific marker of proximal tubule injury, 30 was increased in preeclampsia. KIM-1 is intriguing because it is upregulated by proximal tubule epithelial cells in response to renal ischemia and kidney injury. Expression of KIM-1 converts proximal tubule epithelial cells into professional phagocytes that function like macrophages to remove apoptotic debris from locally damaged tissue. 47 Pertinent to our investigation, in mouse models of renal ischemia, upregulation of KIM-1 in the proximal tubule is specifically mediated by products of complement activation. 48, 49 Remarkably, and consistent with these data, we find that activated complement components show a strong positive correlation with increased urinary KIM-1 levels in human preeclampsia. Similar to mouse models, we also find that markers of terminal complement activation (C5a and C5b-9) rather than upstream activation (C3a) correlate most strongly with KIM-1 levels.
The association between KIM-1 and complement activation in severe preeclampsia is also strengthened by the lack of, or modest, association between complement components and other kidney injury markers in our study. Changes in the urinary excretion of B2M, cystatin C, osteopontin, and uromodulin have been associated with varying forms of kidney injury, 27, 33, [50] [51] [52] [53] [54] [55] 231 but were not different between preeclampsia cases and controls. Increased urine NGAL has been associated with acute kidney injury, 51 ,56,57 but we found levels to be decreased in preeclampsia. EGF has been shown to be decreased in acute renal failure, obstructive nephropathy, and diabetic nephropathy, 29, 58, 59 and we also found decreased urinary levels in preeclampsia. However, decreased excretion of both NGAL and EGF in preeclampsia was independent of complement components and may be influenced by alternative pathways of disease.
Our results suggest that in severe preeclampsia complement activation in the kidney is associated with a localized proximal tubule insult in association with KIM-1. Complement activation likely begins early in pregnancy with local effects at the placental interface, 60, 61 but may ultimately become a systemic process 62 because of shedding of apoptotic or aponecrotic fetoplacental debris into the maternal circulation 63, 64 with resulting systemic inflammation and endothelial activation. 14, 15, 17, 18 Complement proteins may be filtered through an injured glomerulus and basement membrane 65 or may propagate terminal complement activation locally at the proximal tubule, 66 contributing directly to tubular inflammation (C3a, C5a) and cell death (C5b-9). 48, 49 A role for C5 activation in tubular injury is also supported by the finding that C5a receptors in the nephron are concentrated in the proximal tubule 67, 68 and that urinary excretion of C5b-9 correlates with active disease in severe preeclampsia. 20 Considering our finding that terminal complement activation (ie, C5a and C5b-9) in severe preeclampsia is most closely associated with KIM-1, a specific marker of proximal tubule injury, targeted therapeutics to reduce complement activation or proximal tubule injury in severe preeclampsia may be useful in prevention or treatment of disease.
Perspectives
Our findings support the hypothesis that both glomerular damage and proximal tubule injury are central features of disease in severe preeclampsia. Furthermore, it seems that terminal complement activation at the level of C5, generating C5a and C5b-9, may propagate proximal tubule injury in active disease in association with KIM-1. Other measured urinary biomarkers of kidney injury do not seem to be specific for complement-specific effects in preeclampsia, although urinary NGAL and EGF excretion may be decreased in preeclampsia through other pathways. Because of the observational study design, we cannot be certain whether complement activation and proximal tubule injury are simply the final end points of severe disease in preeclampsia or whether such mechanisms are in effect before overt disease. The study is also limited by a small sample size that is underpowered to detect more modest effects between groups and limitations imparted by assessment of urine protein measurements from a single voided specimen. However, it is intriguing to note that complement blockade (at the level of C5) was able to prolong pregnancy for 17 days in a recently reported case of severe preeclampsia. 69 Complement blockade has also been reported to restore kidney function in other severe medical conditions such as atypical hemolytic uremic syndrome, shiga toxin-associated hemolytic uremic syndrome, and catastrophic antiphospholipid antibody syndrome. [70] [71] [72] [73] Severe preeclampsia remains an unpredictable and fulminant disease, but we think there is a compelling rationale to target complement-mediated inflammation and proximal tubule injury in the treatment of preeclampsia. 
